Frontlight ResearchEarly access
CompletedPhase 1/2
NVG-291 in Spinal Cord Injury Subjects
Key facts
- Who runs it
- NervGen Pharma
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 24 people enrolled
- Started
- 8 Aug 2023
- Ended
- 21 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- NVG-291
- Placebo Injection
- Record updated
- 9 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (62)Hide the full registry criteria
Who can take part
- A subject must provide written informed consent in accordance with local regulations prior to initiation of any study-specific activities/procedures. A legally authorized representative (LAR) may be used to assist in signing the informed consent
- Cervical spinal cord injury (SCI) resulting from acute physical trauma
- Males and females
- Age 18 to 75 years, inclusive
- Cervical SCI, incomplete, with a neurological level of injury at C7 or higher
- Had incomplete cervical SCI within the period from 1 year to 10 years inclusive (Chronic Cohort 1) OR within 20 days to 90 days inclusive (Subacute Cohort 2) at time of randomization
- Chronic Cohort 1 only: Must be able to volitionally initiate at least one step on one leg (without body weight support)
- Must have a Walking Index for Spinal Cord Injury II (WISCI II) score as follows:
- Chronic Cohort 1: Less than or equal to Level 14
- Subacute Cohort 2: Less than or equal to Level 10
- Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Prehension Ability score/hand grip strength as follows:
- Chronic Cohort 1:
- Must have a score of at least 2 on at least one of the Prehension Ability grasp patterns of the GRASSP assessment in at least one upper extremity
- Must have no more than one Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above
- Subacute Cohort 2:
- Must have some voluntary (nonzero) force measured by grip dynamometry in at least one upper extremity
- Must have no more than one Prehension Ability grasp pattern score = 3 in at least one upper extremity
- Must not have a Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above
- Presence of Motor Evoked Potentials (MEPs):
- Chronic Cohort 1: In two specific target muscle groups
- Subacute Cohort 2: In one specific target muscle group
- Must be fluent in English
- Must be willing and able to comply with scheduled visits, all sample collections, and other trial procedures
Who cannot take part
- Metal implant in the head that is likely to interfere with MRI analysis
- History of substance abuse within 12 months prior to screening, based on medical records or self-report
- Prior treatment with cell therapy delivered into the central nervous system (intrathecal or intraparenchymal)
- Severe neuropathic pain inadequately controlled by medication
- Received botulinum toxin injection(s) in an upper or lower extremity muscle in the prior 6 months
- Received 4-aminopyridine within 7 days of first dose
- Prior treatment with a protein tyrosine phosphatase sigma (PTPσ) mimetic peptide
- Received a non-permitted medication within 5.5 half-lives or 7 days, whichever is longer, prior to randomization
- Receiving any treatment intended to enhance neuroplasticity (e.g., electrical stimulation, acute intermittent hypoxia) at the time of consent or within 4 weeks of randomization, whichever is longer
- Currently receiving neuromuscular stimulation
- Currently receiving vagal or phrenic nerve stimulation
- Malignancy within 5 years prior to screening, except for non-melanoma skin cancers or cervical or breast ductal carcinoma in situ
- Any disease, concomitant injury (such as significant traumatic brain injury), or condition that could interfere with the performance or interpretation of the protocol-specified assessments, in the opinion of the investigator
- Nontraumatic SCI (e.g., due to infection, ischemia, metabolic abnormality, congenital abnormality, malignancy, radiation injury, surgical complications, or other disease process)
- Any condition that precludes adequate clinical assessment of all four extremities, such as contracture, peripheral nerve injury, or amputation
- History of uncontrolled seizures, or:
- Chronic Cohort 1: Any seizure within the last 6 months
- Subacute Cohort 2: Any seizure occurring 1 week or more after the SCI
- Any neurological condition that is considered to interfere with performance or likely confound assessment, such as multiple sclerosis, stroke, or progressive syringomyelia
- History of a cardiac pacemaker or pacemaker wires
- Prosthetic heart valves
- Any other social or medical condition (e.g., uncontrolled diabetes, unstable hypertension) which, in the opinion of the investigator, would make the subject unsuitable for study participation
- History of medically significant hepatic disease or evidence of impaired liver function based on initial laboratory testing
- Severe renal insufficiency, defined as eGFR < 30 mL/min/1.73m2
- SCI due to gunshot wound or penetrating injury
- Two or more (noncontiguous) spinal cord lesions
- MRI or CT evidence of anatomically complete spinal cord transection
- Any form of ventilatory dependence
- Pregnant or breastfeeding
- Evidence of spinal instability or persistent spinal stenosis and/or compression related to the initial trauma
- Body mass index (BMI) > 40 kg/m2
- Intrathecal opioid use
- Currently participating in an interventional clinical trial
- Any implanted internal spinal cord stimulator
- Chronic Cohort 1 only: Any contraindication to baseline and on-study MRIs, such as:
- Ferromagnetic metallic particles in the body
- Baclofen pump
- Vascular clips in the head
- Severe claustrophobia impeding ability to participate in an imaging study
Where in United States
- Shirley Ryan AbilityLabChicago, United States
About the trial
What the trial wants to find out
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
The 2 groups in the trial
- NVG-291 for SC InjectionTreatment being tested
NVG-291 administered by subcutaneous injection once daily for 12 weeks, with cetirizine pretreatment.
Treatment: NVG-291
- Placebo for SC InjectionPlacebo, for comparison
Matching placebo administered by subcutaneous injection once daily for 12 weeks, with cetirizine pretreatment.
Treatment: Placebo Injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects (CONNECT)
- Publications
- Circuit Reconstruction after Traumatic Spinal Cord Injury by Cellular and Pharmacological Approaches.The Journal of neuroscience : the official journal of the Society for Neuroscience, 2025
- Record updated
- 9 November 2026